Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Birmingham

La Jolla

Orlando

Tampa

Indianapolis

Iowa City

Boston

Detroit

Rochester

Jefferson City

St Louis

Lebanon

Hackensack

Buffalo

New York

Syracuse

Durham

Columbus

Toledo

Charleston

Houston

Burlington

Seattle

Morgantown

Adelaide

Concord

Gosford

Hobart

St Leonards

Graz

Innsbruck

Salzburg

Vienna

Minsk Didtrict

Vitebsk

Bruges

Brussels

Ghent

Kortrijk

Turnhout

Yvoir

Belo Horizonte

Campianas

Caxias do Sul

Curitiba

Goiânia

Porto Alegre

Porto Alegre/rs

Rio de Janeiro

Salvador

SAO Paulo - SP

São Paulo

Pleven

Sofia

Varna

Ottawa

Toronto

Concepción

Santiago

Prague

Arhus C

København Ø

Alexandria

BENI SWEF

Cairo

Dakahlia

Bordeaux

Marseille

Paris

Pessac

Pierre-Bénite

Tours

Berlin

Essen

Freiburg im Breisgau

Göttingen

Homburg/saar

Mainz

München

Ulm

Budapest

Debrecen

Kaposvár

Pécs

Beersheba

Haifa

Jerusalem

Petah Tikva

Ramat Gan

Tel Aviv

Bari

Bologna

Cagliari

Florence

Meldola

Modena

Ravenna

Rimini

Roma

Torino

Durango Durango

México

Monterrey

Monterrey Nuevo LEON

San Luis Potosí City

Maastricht

Nieuwegein

Auckland

Christchurch

Takapuna

Arequipa

Lima

Bydgoszcz

Chorzów

Krakow

Lodz

Warsaw

Wroclaw

Braga

Coimbra

Porto

San Juan

Bucharest

Chelyabinsk

Moscow

Petrozavodsk

Saint Petersburg

Bratislava

Martin

Barcelona

Girona

Madrid

Pamplona

Salamanca

Seville

Valencia

Linköping

Lund

Solna

Ankara

Denizli

Istanbul

Kayseri

Samsun

Birmingham

Cardiff

Liverpool

Manchester

Newcastle upon Tyne

Southampton

Truro